Opportunity Information: Apply for PAR 16 122
Apply for PAR 16 122
- The HHS-NIH11 in the education, health sector is offering a public funding opportunity titled "Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.399.
- This funding opportunity was created on Mar 09, 2016 and posted on Mar 09, 2016.
- Applicants must submit their applications by Sep 07, 2018. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01) (PAR 16-122) is an NIH grant opportunity focused on understanding how lifestyle interventions can influence cancer outcomes after treatment. The central aim is not simply to show that physical activity or weight management helps survivors, but to pinpoint the specific biological and biobehavioral mechanisms that might explain improvements in prognosis and survival. The announcement emphasizes translational, transdisciplinary work that connects behavioral intervention science with cancer biology and related clinical and basic science fields, so that observed benefits can be tied to credible, measurable pathways.
The FOA invites research that tests the effects of physical activity interventions alone or combined with weight control strategies, defined broadly as either intentional weight loss or prevention of weight gain. A major requirement is that proposed studies measure established biomarkers of cancer prognosis that have prior support from animal studies or observational research. Importantly, the opportunity specifically steers applicants away from focusing primarily on insulin and glucose metabolism biomarkers, encouraging attention to other prognostic pathways. Strong applications are expected to leverage biomarker assessments that can plausibly reflect tumor behavior and progression, with particular interest in biomarkers obtained directly from tumor tissue. When feasible and ethically appropriate, the FOA highlights repeat tumor biopsies as a valuable source of tissue-based biomarkers, because they can help clarify whether an intervention is changing the tumor microenvironment or other tumor-related processes over time.
Because many cancer survivors may never experience a recurrence but still face elevated risks from other health conditions, the FOA also encourages inclusion of biomarkers tied to comorbid disease and aging. This includes, for example, biomarkers related to cardiovascular disease risk and markers of aging or early aging phenotypes, reflecting the real-world survivorship context where long-term outcomes may be driven by more than cancer alone. In practice, this means investigators can build studies that examine whether physical activity and weight control affect not only cancer-related prognostic biology, but also pathways that influence overall mortality, functional decline, and chronic disease burden.
From a design standpoint, the FOA strongly favors experimental approaches capable of establishing causal effects. Randomized controlled trials are explicitly encouraged, and the announcement also mentions more complex experimental designs such as fractional factorial designs, which can efficiently test multiple intervention components or combinations (for example, separating the independent and joint effects of exercise and dietary weight control elements). The expectation is that interventions are sufficiently well-defined and measured to allow clear interpretation of biomarker changes attributable to the intervention, rather than relying on correlational associations.
Administratively, this is an R01 research project grant under the U.S. Department of Health and Human Services, National Institutes of Health. It is categorized under education and health funding activities and is associated with CFDA numbers 93.393 and 93.399. Eligibility is broad and includes many organization types such as state and local governments, public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), federally recognized tribal governments and other tribal organizations, public housing authorities/Indian housing authorities, for-profit organizations (excluding small businesses in that specific category), small businesses, and other applicants as described in the NIH eligibility text. The FOA was posted March 9, 2016, with an original and current closing date listed as September 7, 2018.
Overall, the opportunity is geared toward rigorous clinical and translational survivorship research that can move beyond general claims about exercise or weight and instead demonstrate how these interventions affect concrete biological markers linked to cancer prognosis, survival, comorbid disease risk, and aging. The most competitive projects are likely to be those that integrate strong intervention methods, careful biomarker selection grounded in prior evidence, and collaborative teams that can credibly bridge behavioral science and mechanistic oncology.
Frequently Asked Questions (FAQs)
What is the name of this NIH funding opportunity?
The opportunity is titled "Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01)" with the funding announcement identifier PAR 16-122.
What is the main goal of PAR 16-122?
The main goal is to understand how lifestyle interventions (physical activity alone or combined with weight control) can influence cancer outcomes after treatment by identifying specific biological and biobehavioral mechanisms tied to prognosis and survival, rather than only showing that an intervention "works."
What types of interventions does the FOA support?
The FOA supports studies that test physical activity interventions alone or physical activity combined with weight control strategies. Weight control is defined broadly to include intentional weight loss or prevention of weight gain.
What kind of research approach is emphasized?
The announcement emphasizes translational and transdisciplinary research that connects behavioral intervention science with cancer biology and related clinical and basic science fields, so observed survivorship benefits can be tied to credible and measurable pathways.
Are observational studies sufficient for this FOA?
The FOA strongly favors experimental approaches capable of establishing causal effects. Randomized controlled trials are explicitly encouraged, and more complex experimental designs are also mentioned.
What study designs are encouraged?
Randomized controlled trials are explicitly encouraged. The FOA also mentions complex experimental designs such as fractional factorial designs that can efficiently test multiple intervention components or combinations (for example, separating independent and joint effects of exercise and dietary weight control elements).
What is required regarding biomarkers?
A major requirement is that proposed studies measure established biomarkers of cancer prognosis that have prior support from animal studies or observational research.
Does the FOA prioritize certain biomarker pathways over others?
Yes. The opportunity specifically steers applicants away from focusing primarily on insulin and glucose metabolism biomarkers and encourages attention to other prognostic pathways.
What kinds of biomarkers are considered strong for this FOA?
Strong applications are expected to use biomarker assessments that plausibly reflect tumor behavior and progression, with particular interest in biomarkers obtained directly from tumor tissue.
Are repeat tumor biopsies allowed or encouraged?
When feasible and ethically appropriate, the FOA highlights repeat tumor biopsies as a valuable approach for obtaining tissue-based biomarkers. This can help clarify whether an intervention changes the tumor microenvironment or other tumor-related processes over time.
Is the FOA only about cancer recurrence and cancer-specific outcomes?
No. The FOA notes that many cancer survivors may never experience recurrence but can still face elevated risks from other health conditions. It encourages inclusion of biomarkers tied to comorbid disease and aging.
What kinds of non-cancer biomarker areas are encouraged?
The FOA encourages biomarkers related to comorbid disease and aging, including examples such as biomarkers tied to cardiovascular disease risk and markers of aging or early aging phenotypes.
Why include comorbid disease and aging biomarkers in survivorship studies?
The FOA frames survivorship in a real-world context where long-term outcomes may be influenced by more than cancer alone, including overall mortality, functional decline, and chronic disease burden.
What is the grant mechanism used for this opportunity?
This is an NIH R01 research project grant.
Which federal agency and department sponsor this opportunity?
The opportunity is under the U.S. Department of Health and Human Services, National Institutes of Health (NIH).
What funding activity categories are associated with this FOA?
It is categorized under education and health funding activities.
What CFDA numbers are associated with this opportunity?
The announcement is associated with CFDA numbers 93.393 and 93.399.
Who is eligible to apply based on the information provided?
Eligibility is broad and includes state and local governments; public and private institutions of higher education; nonprofit organizations (with or without 501(c)(3) status); federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; for-profit organizations (excluding small businesses in that specific category); small businesses; and other applicants as described in the NIH eligibility text.
When was the FOA posted?
The FOA was posted on March 9, 2016.
What is the listed closing date for applications?
The original and current closing date listed is September 7, 2018.
What would make a project especially competitive for this FOA?
Based on the description, competitive projects are likely to integrate rigorous, well-defined intervention methods; careful biomarker selection grounded in prior evidence; and collaborative teams that credibly bridge behavioral science with mechanistic oncology and related disciplines.
Does the FOA require that intervention components be clearly defined and measured?
Yes. The expectation is that interventions are sufficiently well-defined and measured so biomarker changes can be clearly interpreted as attributable to the intervention rather than correlational associations.
Browse more opportunities from the same category: Education, Health
Next opportunity: Energy Regulatory Partnership Program
Previous opportunity: LACC Develop Youth Skilled Trade at SAMO
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 16 122
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 16 122) also looked into and applied for these:
| Funding Opportunity |
|---|
| The Application of Big Data Analytics to Drug Abuse Research (R01) Apply for PA 16 119 Funding Number: PA 16 119 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Emerging Questions in Cancer Systems Biology (U01) Apply for PAR 16 131 Funding Number: PAR 16 131 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Cancer Research Education Grants Program to Promote Diversity - Research Experiences (R25) Apply for PAR 16 138 Funding Number: PAR 16 138 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $300,000 |
| The Early Detection Research Network: Biomarker Developmental Laboratories (U01) Apply for RFA CA 16 009 Funding Number: RFA CA 16 009 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Coordinating Center for Barrett's Esophagus Translational Research Network (BETRNet)(U24) Apply for RFA CA 16 007 Funding Number: RFA CA 16 007 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $250,000 |
| Cancer Research Education Grants Program to Promote Diversity - Courses for Skills Development (R25) Apply for PAR 16 139 Funding Number: PAR 16 139 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Research Centers for Barretts Esophagus Translational Research Network (BETRNet)(U54) Apply for RFA CA 16 006 Funding Number: RFA CA 16 006 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $900,000 |
| Population Health Interventions: Integrating Individual and Group Level Evidence (R21) Apply for PA 16 147 Funding Number: PA 16 147 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Role of Astrocytes and Astrocytic Networks in Drug Abuse (R21) Apply for PA 16 145 Funding Number: PA 16 145 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Population Health Interventions: Integrating Individual and Group Level Evidence (R01) Apply for PA 16 146 Funding Number: PA 16 146 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Role of Astrocytes and Astrocytic Networks in Drug Abuse (R01) Apply for PA 16 144 Funding Number: PA 16 144 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Revision Applications to R01 Awards for Research on the NCI's Provocative Questions (R01) Apply for RFA CA 16 010 Funding Number: RFA CA 16 010 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $150,000 |
| Revisions to Add Provocative Question-Relevant Research to Active Research Projects (P01) Apply for RFA CA 16 013 Funding Number: RFA CA 16 013 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $150,000 |
| Revisions Applications to P50 Awards for Research on NCI's Provocative Questions (P50) Apply for RFA CA 16 012 Funding Number: RFA CA 16 012 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $150,000 |
| Revision Applications to U01 Awards for Research on the NCI's Provocative Questions (U01) Apply for RFA CA 16 011 Funding Number: RFA CA 16 011 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $150,000 |
| Integrating Biospecimen Science into Clinical Assay Development (U01) Apply for PAR 16 166 Funding Number: PAR 16 166 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $250,000 |
| Novel Strategies for Targeting HIV-CNS Reservoirs without Reactivation (R01) Apply for RFA MH 17 101 Funding Number: RFA MH 17 101 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Novel Strategies for Targeting HIV-CNS Reservoirs without Reactivation (R21) Apply for RFA MH 17 100 Funding Number: RFA MH 17 100 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Pilot and Feasibility Studies Evaluating the Role of RNA Modifications (the 'epitranscriptome') in Cancer Biology (R21) Apply for PA 16 177 Funding Number: PA 16 177 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Exploratory Grants in Cancer Epidemiology and Genomics Research (R21) Apply for PA 16 175 Funding Number: PA 16 175 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 16 122", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.